Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute myeloid leukemia.

F R Appelbaum1, J M Rowe, J Radich

  • 1Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.

Hematology. American Society of Hematology. Education Program
|November 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?

Leukemia·2017
Same author

Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.

Leukemia·2016
Same author

Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.

Leukemia·2016
Same author

Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.

Leukemia·2016
Same author

New drug approvals in acute myeloid leukemia: what's the best end point?

Leukemia·2015
Same author

Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration.

Blood cancer journal·2015
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Advances in understanding acute myeloid leukemia (AML) biology reveal distinct disease subtypes and novel therapeutic targets. Research explores targeted therapies, immunotherapies, and advanced models to improve AML treatment outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute myeloid leukemia (AML) is a complex hematologic malignancy with evolving biological understanding.
  • Recent advances have identified new therapeutic targets and innovative model systems for AML research.

Purpose of the Study:

  • To summarize the current state-of-the-art therapy for adult AML.
  • To highlight the heterogeneity of AML and the importance of cytogenetic markers in treatment selection.
  • To review novel therapeutic strategies including targeted therapies, immunotherapies, and preclinical models.

Main Methods:

  • Review of current adult AML treatment strategies.
  • Analysis of cytogenetic abnormalities and mutations in AML pathogenesis.
  • Exploration of immunotherapeutic approaches (antibody-based, cell-based, vaccines).

Related Experiment Videos

  • Evaluation of the NOD/SCID mouse model for AML research.

    • Main Results:

    • AML is not a single disease but a spectrum of related diseases.
    • Cytogenetic markers and mutations define AML subtypes and guide treatment.
    • Novel therapeutic targets arise from understanding abnormal signal transduction pathways.
    • Immunotherapies and advanced models show promise for future AML treatment.

    Conclusions:

    • Personalized treatment approaches based on AML subtype are crucial.
    • Targeted therapies and immunotherapies represent promising avenues for AML treatment.
    • Preclinical models like NOD/SCID mice are vital for testing novel AML therapies.